Latest Insights - page 15 | BiopharmaTrend

22 Life Science Marketplaces to Try in 2025

A life sciences marketplace is an online platform that operates with a "many-to-many" business logic, hosting multiple suppliers and buyers interacting via various e-commerce tools available as part of the website's functionality.

Continue ›››

Lilly Taps Insilico Medicine's AI in $100M Drug Discovery Collaboration

Insilico Medicine has entered a research and licensing collaboration with Eli Lilly, expanding their existing partnership to jointly discover novel therapeutics using Insilico’s Pharma.AI platform. The collaboration builds on a …

Continue ›››

Insilico Medicine Presents Eight Oral Cardiometabolic Drug Candidates Designed With AI

On November 7, 2025 at BIO-Europe, Insilico Medicine disclosed eight oral small-molecule programs for cardiometabolic diseases discovered with its Pharma.AI platform. The portfolio spans lead identification to IND-enabling and targets …

Continue ›››

New LLMs, Agents, and Graphs in Life Sciences

In recent weeks, Anthropic announced “Claude for Life Sciences” as an AI framework for assisting life science researchers. The release is one of several recent moves by general-purpose AI vendors …

Continue ›››

Five Companies Leading the Way in 3D Bioprinting

Lately, bioprinting is shifting from proof-of-concept prints to regulated workflows and early clinical use. In July 2022 in San Antonio, Texas, surgeons performed the first human ear reconstruction using a …

Continue ›››

Roche and Manifold Bio's up-to-$2B Deal to Develop Next-Gen Brain Shuttles for Neurological Diseases

Manifold Bio, a Boston-based platform therapeutics company, announced a strategic collaboration and license agreement with Roche to develop several next-generation blood-brain barrier (BBB) shuttles intended for neurological and neurodegenerative disease …

Continue ›››

Companies Making Automated Drug Discovery a Reality

Data is king in modern biopharmaceutical research, and ability to generate massive amounts of quality biomedical data represents a tremendous research and business potential in the artificial intelligence (AI)-driven drug discovery …

Continue ›››

7 Biotechs Fighting Rare Diseases With Gene-Editing Tech

Rare diseases sit at an uncomfortable scale: about 30 million people in the U.S., roughly >300 million worldwide. According to NIH, there are an estimated 6,000 to 8,000 rare diseases, …

Continue ›››

Flatiron Health Launches Six AI Blood Cancer Datasets Covering 505,000 Patients

Flatiron Health has launched six new hematology datasets built using AI and large language models (LLMs), unlocking longitudinal clinical data for 505,000 patients with blood cancers. The release marks a …

Continue ›››

Recursion Completes Whole-Genome Microglia Map With Roche and Genentech

Recursion announces the acceptance of its whole-genome Microglia Map by Roche and Genentech, marking the culmination of a three-year collaboration focused on decoding microglial cell biology. The milestone triggered a …

Continue ›››

New AI Reportedly Surpasses AlphaFold 3 in Drug-Protein Binding Prediction

Genesis Molecular AI, in collaboration with NVIDIA, has announced a generative 3D foundation model for protein–ligand structure prediction, Pearl (Placing Every Atom in the Right Location). Genesis reports state-of-the-art results on …

Continue ›››

Flagship's New AI Covalent Chemistry Startup; $50M Commitment and Pfizer Program

Flagship Pioneering announced Expedition Medicines after three years of internal development, committing $50 million to scale a quantum-chemistry-driven generative platform for covalent small-molecule discovery, with programs in oncology, immunology, and …

Continue ›››